2025 News

This repository is under review by NIH for potential modification in compliance with U.S. federal Administration directives.

The overarching goal of the ArchEHR-QA 2025 (pronounced "Archer") shared task is to develop automated responses to patients' questions by generating answers that are grounded in key clinical evidence from their electronic health records (EHRs). The proposed dataset, ArchEHR-QA, comprises hand-curated, realistic patient questions (reflective of patient portal messages), relevant focus areas identified within these questions (as determined by a clinician), corresponding clinician-rewritten versions (crafted to aid in formulating responses), and note excerpts providing essential clinical context.

We are pleased to announce the release of Bridge2AI-Voice v1.0, a dataset designed to advance research into the use of voice as a biomarker of health. This dataset, developed as part of the NIH Bridge2AI initiative, aims to support artificial intelligence research by providing ethically sourced, high-quality voice-derived data linked to clinical information.

Bridge2AI-Voice v1.0 includes 12,523 voice-derived recordings from 306 participants across five North American sites. Participants were selected based on conditions known to affect vocal characteristics, including:

• Voice disorders (e.g., laryngeal conditions affecting phonation)
• Neurological and neurodegenerative disorders (e.g., Parkinson’s, ALS, stroke)
• Mood and psychiatric disorders (e.g., depression, anxiety)
• Respiratory disorders (e.g., asthma, chronic cough)
• Pediatric voice and speech disorders

The initial release does not include raw voice recordings. Instead, it provides derived acoustic features, such as spectrograms, along with detailed demographic, clinical, and validated questionnaire data.

This year's Challenge focuses on detecting Chagas disease from ECGs. Chagas disease is a parasitic disease in Central and South America that affects an estimated 6.5 million people and causes nearly 10,000 deaths annually. Timely treatment may prevent or slow damage to the cardiovascular system, but serological testing capacity is limited, so detection through ECGs can help to identify potential Chagas patients for testing and treatment.